Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies.

EBioMedicine - 1 Jul 2024

Kukendrarajah Kishore, Farmaki Aliki-Eleni, Lambiase Pier D, Schilling Richard, Finan Chris, Floriaan Schmidt Amand, Providencia Rui

Abstract excerpt

BACKGROUND: Drug development for atrial fibrillation (AF) has failed to yield new approved compounds. We sought to identify and prioritise potential druggable targets with support from human genetics, by integrating the available evidence with bioinformatics sources relevant for AF drug development. METHODS: Genetic hits for AF and related traits were identified through structured search of MEDLINE. Genes derived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Atrial Fibrillation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Computational Biology

Share to Drug Development

Share to Drug Discovery

Share to Drug Repositioning

Share to Genetic Association Studies

Share to Genetic Predisposition to Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 38941956
DOI: 10.1016/j.ebiom.2024.105194
PMCID: PMC11260865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies.PMID 38941956Read ↗

Genomic data-driven framework for drug target discovery in atrial fibrillation.Semantic proximity Read ↗

Novel Drug Targets for Atrial Fibrillation Identified Through Mendelian Randomization Analysis of the Blood Proteome.Semantic proximity Read ↗

Genomic approaches to identify and investigate genes associated with atrial fibrillation and heart failure susceptibility.Semantic proximity Read ↗

Genetics and Pharmacogenetics of Atrial FibrillationSemantic proximity Read ↗

Atrial Fibrillation Genomics: Discovery and Translation.Semantic proximity Read ↗

Genetics of atrial fibrillation-practical applications for clinical management: if not now, when and how?Semantic proximity Read ↗

Deciphering the genetic architecture of atrial fibrillation offers insights into disease prediction, pathophysiology and downstream sequelaeSemantic proximity Read ↗

Genetics of Atrial Fibrillation: State of the Art in 2017.Semantic proximity Read ↗

Proteome-wide Mendelian randomization identifies drug targets for atrial fibrillation/flutter.Semantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

A phenome-wide bidirectional Mendelian randomization analysis of atrial fibrillation.Semantic proximity Read ↗

Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.